Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics


Karyopharm Therapeutics Inc. (KPTI): $8.10

0.37 (+4.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

KPTI POWR Grades


  • KPTI scores best on the Growth dimension, with a Growth rank ahead of 88.81% of US stocks.
  • KPTI's strongest trending metric is Quality; it's been moving down over the last 161 days.
  • KPTI's current lowest rank is in the Stability metric (where it is better than 1.7% of US stocks).

KPTI Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for KPTI is -0.94 -- better than only 4.01% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -5.69 for Karyopharm Therapeutics Inc; that's greater than it is for only 2.36% of US stocks.
  • In terms of volatility of its share price, KPTI is more volatile than 85.26% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Karyopharm Therapeutics Inc, a group of peers worth examining would be KMPH, ICPT, BYSI, INSM, and RDUS.
  • KPTI's SEC filings can be seen here. And to visit Karyopharm Therapeutics Inc's official web site, go to www.karyopharm.com.

KPTI Valuation Summary

  • In comparison to the median Healthcare stock, KPTI's EV/EBIT ratio is 108.87% lower, now standing at -2.6.
  • KPTI's EV/EBIT ratio has moved up 18.3 over the prior 95 months.
  • Over the past 95 months, KPTI's price/sales ratio has gone down 1018.6.

Below are key valuation metrics over time for KPTI.

Stock Date P/S P/B P/E EV/EBIT
KPTI 2021-08-31 4.3 -5.3 -2.1 -2.6
KPTI 2021-08-30 4.0 -5.0 -2.0 -2.5
KPTI 2021-08-27 4.1 -5.1 -2.0 -2.5
KPTI 2021-08-26 3.8 -4.6 -1.9 -2.3
KPTI 2021-08-25 3.8 -4.7 -1.9 -2.4
KPTI 2021-08-24 3.7 -4.6 -1.8 -2.3

KPTI Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -74.5%.
  • Its 5 year cash and equivalents growth rate is now at 377.93%.
  • The 4 year net income to common stockholders growth rate now stands at -56.38%.
KPTI's revenue has moved up $118,400,000 over the prior 67 months.

The table below shows KPTI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 118.65 -163.225 -206.229
2021-06-30 102.294 -183.582 -207.912
2021-03-31 113.207 -168.111 -200.756
2020-12-31 108.085 -160.234 -196.273
2020-09-30 91.081 -169.089 -201.499
2020-06-30 82.897 -161.283 -189.371

KPTI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KPTI has a Quality Grade of C, ranking ahead of 58.11% of graded US stocks.
  • KPTI's asset turnover comes in at 0.338 -- ranking 138th of 681 Pharmaceutical Products stocks.
  • CAPR, DRNA, and PLXP are the stocks whose asset turnover ratios are most correlated with KPTI.

The table below shows KPTI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.338 0.965 -0.614
2021-03-31 0.347 0.975 -0.545
2020-12-31 0.299 0.975 -0.534
2020-09-30 0.255 0.967 -0.576
2020-06-30 0.239 0.956 -0.607
2020-03-31 0.189 0.945 -0.671

KPTI Price Target

For more insight on analysts targets of KPTI, see our KPTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.22 Average Broker Recommendation 1.6 (Moderate Buy)

KPTI Stock Price Chart Interactive Chart >

Price chart for KPTI

KPTI Price/Volume Stats

Current price $8.10 52-week high $17.39
Prev. close $7.73 52-week low $4.42
Day low $7.63 Volume 636,409
Day high $8.20 Avg. volume 1,965,692
50-day MA $7.26 Dividend yield N/A
200-day MA $7.66 Market Cap 611.93M

Karyopharm Therapeutics Inc. (KPTI) Company Bio


Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.


KPTI Latest News Stream


Event/Time News Detail
Loading, please wait...

KPTI Latest Social Stream


Loading social stream, please wait...

View Full KPTI Social Stream

Latest KPTI News From Around the Web

Below are the latest news stories about Karyopharm Therapeutics Inc that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

H.C. Wainwright Keeps a Buy Rating on Karyopharm Therapeutics (KPTI)

E ratio of -2.81.

Howard Kim on TipRanks | January 11, 2022

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Karyopharm Therapeutics (KPTI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Beam Therapeutics (BEAM – Research Report) and Karyopharm Therapeutics (KPTI – Research Report). Beam Therapeutics (BEAM) In a report released today, Rick Bienkowski from Leerink Partners maintained a Buy rating on Beam Therapeutics, with a price target of $121.00. The company's shares closed last Monday at $69.49, close to its 52-week low of $56.34. According to TipRanks.com, Bienkowski is ranked #7089 out of 7758 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beam Therapeutics with a $122.00 average price target, representing a 73.0% upside.

Christine Brown on TipRanks | January 10, 2022

Karyopharm reports prelim Q4 revenues, outlines 2022 objectives

Karyopharm Therapeutics <> expects net product revenues of XPOVIO to be ~$29.7M for Q4 and ~$98.3M for FY21."For 2022, we are focused on making significant advances across

Seeking Alpha | January 10, 2022

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer. She will be responsible for leading the Company's commercial strategy and operations, including the continued commercialization of XPOVIO® (selinexor). Ms. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations.

Yahoo | January 10, 2022

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the Company's first-in-class, oral XPO1 inhibitor, and outlined its 2021 achievements and 2022 objectives.

Yahoo | January 10, 2022

Read More 'KPTI' Stories Here

KPTI Price Returns

1-mo 13.60%
3-mo 53.70%
6-mo -8.37%
1-year -46.22%
3-year -11.57%
5-year -22.04%
YTD 25.97%
2021 -58.46%
2020 -19.25%
2019 104.59%
2018 -2.40%
2017 2.13%

Continue Researching KPTI

Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:

Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8077 seconds.